**WHRI Website:**

**Research Project Template**

Please complete one form per research project/program you would like displayed on the WHRI website. This page will provide you with a space to help recruit participants, disseminate findings and showcase other knowledge translation activities resulting from the study. The content you provide in this form will be connected to the research team’s bios provided by the membership information. If any of these fields do not apply to this project, please leave them blank.

If there are supporting documents you would like embedded on the project page (i.e. consent forms) or if you have any questions regarding this form, please contact Nicole Prestley at Nicole.Prestley@cw.bc.ca or by phone **604-875-2424 ext 4956**.

|  |  |
| --- | --- |
| **Title:** (same as consent form) | Quadrivalent vaccine evaluation study (QUEST) |
| **Principal Investigator:** | Gina Ogilvie, Simon Dobson |
| **Primary Contact:**(name, title, phone, email) | QUEST Coordinating CentreTel: 604.875.2636Toll Free: 1.866.502.2424Email: questhpvstudy@cfri.ca |
| **About the Study:**(100 words or less plain language summary) | QUEST (Quadrivalent HPV Vaccine Evaluation Study) is a Canada-wide study designed to evaluate whether 2 doses of the HPV vaccine are just as effective as 3 doses at preventing Human Papillomavirus (HPV) infection and cervical cancer. The QUEST study will seek to recruit 8,666 females from across between the ages of 14 to 18. Study sites are in British Columbia, Alberta, Quebec, Nova Scotia, and PEI. |
| **Why is this research important?** | A 2 dose schedule instead of 3 doses of the HPV vaccine means girls would have to endure fewer shots and the program could be extended to more people including boys. Fewer doses means that middle and lower income countries are more likely to be able to afford the HPV vaccine program. |
| **Study Status:**(e.g. recruiting, data analysis, manuscript development, complete) | Currently recruiting |
| **Who can participate:**(short description, attach consent form) | Females 14-18 years old who received either 2 or 3 doses of the HPV vaccine on the provincial scheduleLocated in BC, Alberta, Quebec, PEI, Nova Scotia<http://questhpvstudy.ca/contact-us/> Participating is quick and simple and can be done from anywhere. Participants are enrolled in the study for 5 years and involves completing an online survey once a year and providing self collected swabs twice a year |
| **Study Results/Publication:** | Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer. 2015;137(8):1931-7.Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2014;32(5):624-30.Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802. |
| **Co-Investigators:** | Mel Krajden, Joel Singer, Marie Helene Mayrand, Shelly McNeil, Chantal Sauvageau, Vladmir Gilca, James Kellner, Deborah Money  |
| **Funded by:** | MSFHR, CIHR |
| **Partners:** | UBC, CFRI, Dalhousie University, University of Calgary, Centre Hospitalier Universitaire de Quebec |
| **Other Attachments:**(e.g. Newsletters, videos) | <http://questhpvstudy.ca/>  |